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Abstract
Background: Asthma that is poorly controlled and undertreated can progress to more severe disease that is associated with
high levels of unscheduled care that requires high-cost therapy, leading to a significant health economic burden. The identification
and appropriate referral to a specialist asthma service is also often delayed by several months or years because of poor recognition
and understanding of symptom severity. Current severe asthma services may take several months to provide a comprehensive
multidisciplinary assessment, often necessitating multiple hospital visits and costing up to £5000 per patient.
Objective: This study aims to evaluate whether a new service model could identify poorly controlled and potentially severe
asthma much earlier in the patient pathway, and then compare clinical outcomes between this new care model with standard care.
Methods: Modern Innovative Solutions to Improve Outcomes in (MISSION) Severe Asthma is a novel service model developed
by asthma specialists from Portsmouth and Southampton severe asthma services. MISSION Severe Asthma identified patients
with poorly controlled disease from general practice databases who had not been under secondary outpatient care in the last 12
months or who were not known to secondary care. In 1- or 2-stop assessments, a thorough review of diagnosis, disease phenotype,
and control is undertaken, and clinical outcomes collected at baseline.
Results: A variety of clinical outcomes will be collected to assess the service model. The results will be reported in February
2020.
Conclusions: This protocol outlines a mixed methods study to assess the impact on disease control, unscheduled health care
usage, and quality of life in patients seen in the MISSION clinic compared with a closely matched cohort who declined to attend.
International Registered Report Identifier (IRRID): DERR1-10.2196/9585
(JMIR Res Protoc 2019;8(10):e9585)  doi: 10.2196/resprot.9585
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Introduction
Background and Rationale
The Burden of Disease
Asthma affects 5.4 million patients in the United Kingdom with
the majority of costs (nearly 80%) relating to treating poorly
controlled asthma, amounting to over £1 billion per annum as
a direct cost and an indirect cost to society (time off work and
lost productivity) of £6 billion. In the past year, the Wessex
Region has seen over 1800 emergency adult hospital admissions
because of asthma (over 300 more than expected based on the
national average), costing over £2.1 million to the local health
authority.
Asthma UK highlights that over half of the people with asthma
suffer debilitating symptoms despite being prescribed treatment
[1]. Poorly controlled disease leads to exacerbations
necessitating unscheduled care and high-cost medications while
impairing a patient’s quality of life and increasing the risk of
premature death. In 2009, there were 1131 deaths because of
asthma in the United Kingdom, triggering a Department of
Health–commissioned National Audit of Asthma Deaths [2].
Reviews of asthma deaths have confirmed that those with the
most severe, frequently exacerbating disease are at greatest risk
of death. The Outcome Strategy for Chronic Obstructive
Pulmonary Disease and Asthma recognized this huge burden
on both patients and the National Health Service (NHS) and
outlined the political commitment to improve asthma control
and reduce asthma-related emergency health care needs and
deaths [3]. Asthma UK also highlighted the need to improve
the quality of life of people with asthma by improving access
to services, reducing inequalities in care, and ensuring a high
standard of care. It is accepted that the proactive clinical review
of people with asthma improves clinical outcomes and the
majority with poorly controlled asthma can achieve good
control. The recent publication “NHS five-year forward view”
identifies the traditional separation of primary and secondary
care being a barrier to the integrated care that patients with
chronic disease require [4].
The Unmet Need
The Specialised Services Pathway for Severe Asthma recognizes
the burden of uncontrolled disease ordinarily amenable to
antiinflammatory medications and the progression to longer
term “severe” disease, necessitating high-cost therapies (e.g.
bronchial thermoplasty) [5]. The identification and appropriate
referral to a specialist asthma service is often delayed by several
months or years because of poor recognition and understanding
of symptom severity.
Current severe asthma services may take several months to
provide a comprehensive multidisciplinary assessment often
necessitating multiple hospital visits and costing up to £5000
per patient. The report “Fighting for Breath” highlighted these
issues with service delivery recommending that referral
pathways to severe asthma services should be improved [6].
Description of Clinical Intervention and Treatment
Modern Innovative Solutions to Improve Outcomes in
(MISSION) Severe Asthma is a novel service model pilot that
took place in June and July 2014. MISSION was developed by
asthma specialists from Portsmouth and Southampton asthma
services.
The MISSION concept involved a “carousel clinic” which brings
together all the assessments and investigations a patient requires
into one clinic—the patient moved around each assessment or
“investigation station” in a serial fashion. This allowed the
research team to efficiently gather all the data required for both
staff and the patient. This severe asthma patient journey was
mapped and opportunities for improvement were identified such
as earlier diagnosis by active case finding of at-risk patients,
followed by a swift multidisciplinary assessment which meant
patients could be seen sooner and assessed more effectively.
Patients attending standard outpatient services undergo basic
lung function, chest x-ray, and medical review. They are then
referred for other tests or specialist opinions as required at
different time-points
MISSION Severe Asthma identified patients with poorly
controlled disease from general practice (GP) databases who
had not been under secondary outpatient care in the last 12
months or who were not known to secondary care. The patients
were then invited to Rapid Access Asthma Clinics (RAACs)
for assessment at their GP surgery on a Saturday, at a time
convenient for them. The clinics were held on Saturdays at a
time better suited to the needs of asthma patients, many of whom
are working or studying full-time.
The RAAC delivered a comprehensive asthma review including
assessments of allergic status, airway inflammation, education,
self-management planning, and smoking cessation leading to a
written personalized 1-year asthma management plan for their
GP providing clear treatment recommendations for those with
uncontrolled but treatable asthma (see Figure 1). Treatment
recommendations were in line with current asthma guidelines.
JMIR Res Protoc 2019 | vol. 8 | iss. 10 | e9585 | p. 2https://www.researchprotocols.org/2019/8/e9585
(page number not for citation purposes)
Roberts et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
Figure 1. MISSION Severe Asthma Rapid Access Asthma Clinic flow chart. MISSION: Modern Innovative Solutions to Improve Outcomes.
At the end of the RAAC, a multidisciplinary team (MDT)
meeting was held and treatment plans were discussed. The
possible outcomes for patients included increasing or decreasing
medication, referral for research study, referral to other medical
teams, or a need for further assessment as the patient has
potentially severe and uncontrolled asthma. Patients with
potentially severe and uncontrolled asthma were invited for a
more detailed multidisciplinary specialist assessment at a Severe
Asthma Assessment Clinic (SAAC) again on a Saturday, held
at Queen Alexandra Hospital.
MISSION SAAC included multidisciplinary assessment
respiratory specialists, dieticians, physiotherapists, ear, nose,
and throat (ENT) consultants, physiologists, psychologists, and
pharmacists. Computed tomography (CT) scanning of the chest
and sinus as well as flexible nasendoscopy to assess for sinus
change and nasal polyps was available on that day. Patients saw
the appropriate specialists based on the clinical history from
the RAAC and a medical assessment on arrival to the SAAC.
This ensured full lung function, inhaler technique, and medical
exam for all patients, and physiotherapy, dietician, ENT, CT
chest or sinus were performed where needed (see Figure 2).
Representatives from Allergy UK also attended the clinic and
provided advice and support to patients who were interested.
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Figure 2. MISSION Severe Asthma Rapid Access Asthma Clinic flow chart. CT: computed tomography; ENT: ear, nose, and throat; FeNO: fractional
exhaled nitric oxide; MDT: multidisciplinary team; MISSION: Modern Innovative Solutions to Improve Outcomes; PFT: pulmonary function test.
At the end of the clinic, a full MDT meeting was held to discuss
each case. Patients and their GP received a detailed letter with
all the test results and treatment changes as well as plans for
follow-up. Follow-up referrals were made to specialists as
needed, and treatment changes were made on the day of the
clinic visit with support from the pharmacy for new treatment
prescriptions.
In summary, the difference of the MISSION clinic from standard
care was in 2 areas: First the active case finding of patients who
are not already known to secondary care but are potentially
uncontrolled. The second is the model of the clinic. Patients
seen at the RAAC only will undergo more extensive testing and
review of their asthma than primary care can provide and will
have their comorbidities identified, asthma phenotyped, and
treatment changes made appropriately.
Rationale for Study and Potential Impact
MISSION is a new and novel way of delivering highly
specialized asthma care and has the potential to change the way
asthma care is delivered across the United Kingdom as well as
services for other long-term health conditions. The MISSION
model is the first model of this type, and this study aimed to
evaluate its success and compare the MISSION service with
current care delivery. This will be done in several different
ways. The study is a mixed methods evaluation of the new
service comparing outcomes before and after the MISSION
clinic using retrospective data analysis and prospective
qualitative interviews. A control arm of patients not exposed
to, but eligible for, the new MISSION clinic will also be
included.
Objectives
Using quantitative and qualitative methods, our objective is to
explore the impact of the MISSION service on clinical outcomes
and patient experience. Using quantitative methods, we will (1)
retrospectively analyze data collected as part of routine clinical
care from all patients attending MISSION e.g. asthma control,
medication usage and technique, exacerbations, comorbidities,
allergies, and investigations (blood tests, radiological imaging,
and nasendoscopy) and (2) retrospectively compare the
assessment of comorbidities, investigations, and treatments
between MISSION SAAC patients and standard outpatient care.
Primary Objectives
The primary objectives of this study are as follows:
1. To assess whether asthma control (assessed by exacerbation
history, Asthma Control Questionnaire (ACQ), health care
utilization, and short-acting beta-agonist (SABA) usage) is
improved in MISSION SAAC patients compared with
patients undergoing standard outpatient secondary asthma
care at 6 months.
2. To assess whether asthma control (assessed by exacerbation
history, health care utilization, and SABA usage) is
improved in MISSION RAAC patients compared with those
who were eligible for MISSION but did not attend.
3. To assess whether asthma control (assessed by exacerbation
history, health care utilization, and SABA usage) is
improved after attending the MISSION RAAC and SAAC.
Secondary Objectives
1. To conduct a prospective qualitative study exploring
patients’ experience, understanding and perceptions of their
asthma as well as views on MISSION.
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2. To explore the acceptability of MISSION as a service model
for patients, staff, and the NHS.
3. To retrospectively compare a clinical case finding approach
in primary care with a computer-assisted interrogation on
primary care records.
4. To assess the health economic impact of the MISSION
service.
5. To phenotype patients with uncontrolled or severe asthma
in primary care and gain more information about the asthma
population in Wessex.
6. To assess whether asthma comorbidities are assessed in
standard outpatient care.
7. To assess waiting times and times to specialist referral in
MISSION and standard outpatient care.
Methods
Study Design
A mixed methods observational study evaluating the new
service, comparing outcomes before and after the intervention,
and including a control arm of patients not exposed to, but
eligible for, the new intervention is included. This will include
analyses of the MISSION participants (attending both the RAAC
and SAAC clinics), patients from the existing asthma service
(from outpatient severe asthma clinics), and data from patients
on GP records who were eligible to attend MISSION but did
not (primary care patients). Finally, qualitative methods will be
used to explore participant and health care professionals’ views
on MISSION. Multimedia Appendix 1 summarizes the
participants journey and the different populations under study.
The MISSION Severe Asthma project has not been designed
as a randomized controlled trial (RCT) but designed to evaluate
a novel service model (the intervention) in participants with
uncontrolled and potentially severe asthma, to assess whether
it is deliverable and acceptable by participants and health care
professionals, and to explore the barriers that would need to be
addressed before a larger RCT.
A patient advisor reviewed all patient-facing documentation for
the study and will give advice and feedback on the structure of
the qualitative interviews.
Study Participants
Participants with uncontrolled or potentially severe asthma were
identified from GP records by the MISSION team and new
referrals to an asthma specialist clinic at Queen Alexandra
Hospital between May and August 2014.
Study participants for qualitative interview will be recruited
from patients who attended MISSION SAAC days and staff
who attended MISSION RAAC or SAAC days. Qualitative
one-to-one interviews will be held over the telephone.
Data for quantitative analysis will be collected from records
made by the clinical team during the MISSION RAACs and
SAACs and asthma outpatient clinics. GP records will be entered
as usual by the GP. No extra data will be collected.
Eligibility Criteria
The participant must meet all of the following criteria to be
considered eligible for the study:
• Male or female, aged 18 years or older.
• Is in one of the following population groups:
• Attended the MISSION RAAC or
• Attended the MISSION SAAC or
• Identified as uncontrolled asthma by record searches
and invited to the MISSION RAAC but did not attend
“primary care patients” or
• Has been referred to the specialist asthma clinic at
Queen Alexandra Hospital “outpatient severe asthma
patients” or
• Attended the MISSION RAAC or SAAC as a health
care professional
• Participant is willing and able to give informed consent for
participation in the study.
Primary and Secondary Endpoints and Outcome
Measures for Quantitative Study
Primary Outcome Measure for All Patients
The primary endpoint is asthma control as measured by
exacerbation frequency (defined as deterioration in symptoms
requiring ≥30 mg prednisolone or equivalent for ≥3 days).
Secondary Outcome Measures for Modern Innovative
Solutions to Improve Outcomes in Severe Asthma
Assessment Clinic Patients and Outpatient Severe
Asthma Clinic Patients
1. SABA use measured by the number of inhalers prescribed
in 6 months pre- and post-MISSION or outpatient clinic.
2. Exacerbation frequency (defined as deterioration in
symptoms requiring ≥30 mg prednisolone or equivalent for
≥3 days) in 6 months pre- and post-MISSION or outpatient
clinic.
3. Health care usage costs for asthma and number of contacts
(GP visits, emergency department [ED] or out-of-hour
[OOH] attendances, hospital admissions, and emergency
GP visits) over 6 months pre- and post-MISSION or
outpatient clinic.
4. Assessment of comorbidity (rhinosinusitis, anxiety and
depression, dysfunctional breathing, gastro esophageal
reflux, and obstructive sleep apnea) and method of
assessment.
5. Assessment of inhaler technique and recommendations for
inhaler devices.
6. Smoking cessation advice.
7. Investigations performed during 6 months in secondary
care, for example, full lung function, sputum induction, and
performing a high-resolution CT scan of the chest.
8. Time from GP referral to first clinic visit in secondary care.
9. Time between first and second visit in secondary care.
10. Time to appointment with other specialists for
asthma-related comorbidity where indicated, for example,
dietician, ENT, physiotherapist, psychologist, and CT
imaging.
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11. Assessment of eosinophilic airways inflammation through
measurement of fractional exhaled nitric oxide (FeNO).
12. The frequency of nonattendance at clinic.
Secondary Outcome Measures for Modern Innovative
Solutions to Improve Outcomes in Rapid Access Asthma
Clinic Patients
1. SABA use measured by the number of inhalers prescribed
in 6 months pre- and post-MISSION clinic.
2. Exacerbation frequency (defined as deterioration in
symptoms requiring ≥30 mg prednisolone or equivalent for
≥3 days) during the 6 months pre- and post-MISSION.
3. Frequency and severity of comorbidities.
4. Frequency and type of allergy.
5. Measurement of exhaled nitric oxide.
6. Measurement and variation of lung function.
7. Frequency and type of additional asthma control medication.
8. Disease control and quality of life as assessed by ACQ and
Asthma Quality of Life Questionnaire (AQLQ).
9. Number of patients having measurement of forced
expiratory volume in 1 second (FEV1)÷forced vital capacity
(FVC) as a proxy for asthma control and severity.
Secondary Outcome Measures for Modern Innovative
Solutions to Improve Outcomes in Rapid Access Asthma
Clinic Patients and Primary Care Patients
1. Prescription of SABAs during last 6 months at baseline and
6 months.
2. Exacerbation rates (defined as deterioration in symptoms
requiring ≥30 mg prednisolone or equivalent for ≥3 days)
during the last 6 months at baseline and 6 months.
3. ED attendances, OOH contacts, and hospital admissions
during the last 6 months at baseline and 6 months.
4. Inhaled steroid doses and usage.
5. Number of patients having measurement of FEV1÷FVC as
a proxy for asthma control and severity.
6. The sensitivity and specificity of the PRIMIS (Primary Care
Information Services, University of Nottingham) Asthma
Audit Tool in identifying the patients compared with gold
standard specialist assessment and interrogation of primary
care records.
Screening and Enrollment
Quantitative
All patients from the RAACs and all primary care patients will
be approached for consent to use their anonymized data from
the MISSION clinics or from GP records for research purposes.
No extra data for research purposes will be collected for the
quantitative analysis from patients at MISSION assessments,
asthma outpatient clinics, or GPs.
Qualitative
Patients
All patients who attended MISSION SAACs will be approached
to take part in qualitative one-to-one telephone interviews.
Health Care Professionals
Health care professionals who worked at the MISSION clinics
from both primary and secondary care will be approached for
qualitative interview. All health care professionals will be
approached with an estimated 10 to be interviewed from primary
care and 10 from secondary care. They will be contacted by
email or telephone and, if interested, they will be sent a written
information sheet by email or post. They will also be given
contact details if they have any further questions regarding what
is required to take part. If willing to take part, they will be sent
a consent form to fill in and return to the study team.
Recruitment
Modern Innovative Solutions to Improve Outcomes in
Rapid Access Asthma Clinic and Severe Asthma
Assessment Clinic Patients
All patients who attended the MISSION RAACs (quantitative)
and SAACs (quantitative and qualitative) will be contacted by
telephone to discuss the study and then, if they are interested,
will be sent a patient information sheet (PIS) and consent form
with a covering letter.
If the patient is unable to be contacted by telephone, they will
be sent a covering letter from the MISSION team inviting them
to take part in the study. They will be provided with a number
to contact if they have any questions. They will be given the
opportunity to read the PIS, and if they agree to take part in the
study, they can return the consent form by post in a stamped
addressed envelope.
Primary Care Patients
Patients in primary care will be contacted as described above.
Outpatient Severe Asthma Patients
Patients who attended outpatient clinics as new referrals in June
and July will be approached by telephone after being identified
from the clinic attendance list. If the patient is willing, they will
be sent a PIS and consent form to send back to the study team
in a stamped addressed envelope.
Health Care Professionals
Health care professionals who attended the MISSION RAACs
or SAACs will be contacted by email or telephone to explain
the study and then sent a PIS by email or post if they are
interested in taking part. They will be given time to read the
PIS, and if they wish to take part, they will be asked to return
a consent form in a stamped addressed envelope.
Quantitative Data Collection
Retrospective notes review at 6 months after the MISSION
clinics will be performed to collect the following data. Data
collected by study group are detailed in Table 1. Where
information is not written in medical notes or clinic letters, it
will be marked as not assessed.
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Table 1. Schedule of procedures at the Severe Asthma Assessment and Rapid Access Asthma Clinics.
MISSION Rapid Access Asthma Clinics
and primary care patients
MISSIONa Severe Asthma Assessment
Clinics and outpatient severe asthma
Study group
✓✓bFull medical and asthma history
✓✓Lung function testing
✓✓Inflammometry
✓✓Medication history
✓✓Health care usage (general practitioner attendances, emer-
gency department attendances, and admissions)
✓✓Allergy status
✓✓Smoking status and history
✓✓Inhaler technique before and after review and documenta-
tion of improvements made
✓✓Disease-specific scores: Asthma Control Questionnaire
and Asthma Quality of Life Questionnaire
✓✓Comorbidity screening: Epworth Sleepiness Scale, Sino
Nasal Outcome Test -22, Hospital Anxiety and Depression
Scale, Gastroesophageal Reflux Disease Questionnaire,
and Nijmegen
Xc✓Reviews by wider asthma multidisciplinary team, including
time from referral to review
aMISSION: Modern Innovative Solutions to Improve Outcomes.
b✓: assessment performed.
cX: assessment not performed.
Modern Innovative Solutions to Improve Outcomes in
Severe Asthma Assessment Clinic Patients and
Outpatient Severe Asthma Patients
Retrospective notes review at 6 months after the MISSION
clinics will be performed to collect the following data for
MISSION SAACs and asthma outpatients. The clinical record
form used for the MISSION SAACs is shown in Multimedia
Appendix 2.
Where information is not written in medical notes or clinic
letters, it will be marked as not assessed. Information will
include the following:
• Medical history including asthma history, asthma triggers,
allergy history, past medical history, family history, and
occupation.
• Lung function including peak flow, FEV1, FVC, transfer
factor of the lung for carbon monoxide, CO transfer
coefficient, and FeNO.
• Medication history including asthma and non-asthma
medication.
• Exacerbation history including number of steroid courses,
hospital admissions, and intensive treatment unit
admissions.
• Health care usage including nonroutine GP attendances,
OOH contacts, and ED attendances in 6 months pre- and
post-MISSION SAAC or outpatient clinic.
• Allergy testing results and whether done.
• Smoking status, and if current smoker, whether any smoking
cessation advice or referral was done.
• Inhaler technique—whether checked, any improvements
made, and recommendations for inhaler devices.
• Investigations performed and time in days after first visit.
• ACQ score.
• AQLQ score.
• Sino nasal outcome test-22 (measure of sino nasal
symptoms) score.
• Epworth sleepiness score (measure of somnolence, which
can be caused by obstructive sleep apnea).
• Hospital anxiety and depression scale score.
• Nijmegen (assessment of hyperventilation syndrome) score.
• Gastroesophageal Reflux Disease Questionnaire (assessment
of gastroesophageal reflux) score.
• Time of GP referral, first clinic visit, and second clinic visit.
• Time of referral and appointment with other specialities,
for example, ENT, dietician, and physiotherapy.
Modern Innovative Solutions to Improve Outcomes in
Rapid Access Asthma Clinics
• Lung function including FEV1, FVC, peak flow, and FeNO.
• ACQ and AQLQ at baseline, 3 months, and 6 months in
MISSION RAAC patients.
• Medication history for the last 12 months.
• Exacerbation history for the last 12 months.
• OOH, hospital, and emergency department attendances
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Qualitative Data Collection
Modern Innovative Solutions to Improve Outcomes
Severe Asthma Assessment Clinic Patients
The target population for the qualitative telephone interviews
is all of the 20 patients who attended the MISSION SAACs.
All patients in this group will be approached for an interview.
Participants from MISSION SAACs who are taking part in
qualitative interviews will have 1 telephone interview as part
of this evaluation research study.
Interviews will be arranged at a mutual date and time of
convenience. The researcher will make the telephone calls to
minimize costs to the participants and facilitate audio recordings.
Interviews will be held in a semistructured manner using a topic
guide with relevant prompts. This will allow patients to focus
discussion on the issues important to them and hear their
experiences and views in their own words with free discussion
guided by the patient.
The areas explored will include the patients’ perceptions,
understanding, fears, and concerns about their asthma as well
as their views on MISSION—problems, barriers, and positive
experiences. The interview will explore asthma and asthma
service delivery.
The topic guide will be developed in conjunction with the
payment protection insurance advisor.
Health Care Professionals
Telephone interviews will also be held with medical staff from
both primary and secondary care who worked at the clinics. The
anticipated number of participants will be 10 from primary care
and 10 from secondary care. All staff who attended the
MISSION clinics will be approached for consent. The interviews
will explore the health care professionals’ thoughts on MISSION
and its strengths and weaknesses as well as any suggestions for
improvement. The interviews will also explore the health care
professionals’ understanding and training in severe asthma and
any areas where they would wish to see improvement.
Interview Structure
The semistructured interviews will be conducted by telephone
and audio-recorded with notes taken. Telephone interviews have
been chosen as participants live over a wide geographical area,
and it will allow flexibility with interview times to accommodate
participants’ work and other commitments.
The interviews will be conducted by one of the health care
professionals involved in the clinic. By having an existing
relationship with the study participants and by the interviewer
being a health care professional, the participant may be more
willing to share experiences and personal views [7,8]. The
researcher will be aware of the potential conflict with the
professional role and the role as interviewer and will ensure
open questions are asked [9]. The skills required during a clinical
consultation have considerable overlap with the skills in
qualitative interview [7,9]. It is important that the relationship
between the interviewer and interviewee is clear when planning
the qualitative interview [10] as it is recognized that this can be
a factor in the interview.
At the beginning of the interview, patient participants will be
reminded that the interview topic guide can be deviated, that
they are free to suggest topic areas relevant to their experience
and tell their experiences in their own words, and that there are
no right or wrong answers but to share with the interviewer their
thoughts, both the positives and negatives about MISSION,
living with asthma, and asthma care.
There is also a concern that the patient participants may raise
health questions or ask for health care advice. This will be
addressed by explaining at the beginning of the interview that
the interview is not a clinical consultation; however, any
questions can be answered at the end of the interview.
Interview Analysis
The interviews will be digitally audio-recorded and transcribed
by a professional transcription company. The data will be
entered into a software program to facilitate qualitative analysis
(NVivo10, QSR International (UK) Ltd, London, UK). All
participants’ names will be removed from the transcripts to
retain confidentiality. When writing the results, no quotes will
be directly attributed to participants. Participants will be given
the opportunity to read and approve the transcript. The transcript
will be sent to participants, and if no response is heard within
2 weeks, the transcript will be included in the analysis.
The results from the interview will be analyzed using a thematic
and framework analysis, which uses a 5-step approach to
analyzing and writing up data [11]. This involves familiarization
with the interviews, identifying themes, indexing the themes
onto the interview transcripts, charting, and mapping the themes.
The themes from the patient and health professionals’ interviews
can be compared. This will enable key themes to be
systematically identified and to map the themes from the patients
against those from the health care professionals. A random
sample of 5 interviews will also be independently assessed by
the supervisor to review the themes and analysis undertaken.
The interviews will take between 45 min to 1 hour to complete
depending on what the participants share with the interviewer.
The interview can be terminated at any point the participant
wishes to stop, and this will not influence their subsequent
treatment.
Sample Size
The study was powered to show a difference between the
MISSION group and the primary care group for the primary
outcome, exacerbation frequency. The sample size was based
on an analysis of covariance (ANCOVA) approach, with the
outcome being exacerbation frequency in the second 6-month
period and with the exacerbation frequency in the first 6-month
period being the covariate. Baseline data suggest a mean number
of exacerbations for this group of 1.29, with an SD of 1.30.
There is expected to be no change in exacerbation frequency
between time periods for the primary care group, whereas it is
anticipated that exacerbations in the MISSION group may
reduce by 50% to 0.65 exacerbations. A correlation between
the exacerbation rates in the 2 time periods of 0.5 is assumed.
The primary care group will be larger, with an anticipated 3:1
ratio. To show a difference between groups with a 5%
significance level and 90% power, it is calculated that 44
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subjects in the MISSION group and 132 in the primary group
are required.
Data Analysis
Description of Analysis Populations
All data collected will be analyzed. There will be an analysis
of the MISSION and outpatient groups separately. We will
analyze 4 groups of participants: (1) qualitative assessments in
participants attending the severe clinic, (2) health professionals
attending either of the rapid or severe clinics, (3) quantitative
assessments between those attending the rapid clinic in primary
care to those invited but did not attend, and (4) those who
attended the severe clinic compared with those routinely
attending the outpatient severe asthma clinics in hospital.
Analysis of Endpoints
The analyses will compare the study outcomes between the 4
study groups.
The primary outcome is exacerbation frequency. This outcome
will be analyzed using ANCOVA, with the outcome variable
being exacerbation frequency in the second 6-month period and
the exacerbation rate in the first 6-month period treated as the
covariate. Owing to the likely skewed distribution of the
exacerbation frequency, it may be necessary to perform a log
transformation of the outcome before analysis. Comparisons
will be made overall between the 3 groups, and specifically
between the MISSION group and each of the other 2 groups.
The analysis of secondary outcomes measured on a categorical
scale during the second 6-month period will be compared
between groups using Fisher exact test. Continuous variables
will be compared between groups using analysis of variance, if
found to be normally distributed, or the Kruskal-Wallis test, if
not found to be normal.
Comparisons between groups will also be made accounting for
the values during the first time period. ANCOVA will be used
for continuous variables, whereas logistic regression will be
used for binary outcomes.
Discontinuation and Withdrawal of Participants From
Study Treatment
Participants may withdraw at any point in either the qualitative
or quantitative aspects of the study.
Definition of End of Study
The end of study is the date of the last qualitative interview of
the last participant.
Procedure for Dealing with Missing, Unused, and
Spurious Data
All data collected will be included in the analysis.
Procedures for Reporting Any Deviation(s) From the
Original Statistical Analysis Plan
The study will analyze observational data retrospectively, and
so we do not anticipate any significant deviations as would be
expected in a longitudinal study.
Interim Analysis and Criteria for Early Study
Termination
No interim analyses will be performed.
Dissemination
Patient volunteers and patients who have taken part in the
qualitative interviews will be invited to help with dissemination
events. The results will be submitted for presentation at national
conferences. There will also be reports on the Wessex Asthma
Network website for patients and public to access [12]. All study
participants will be given a summary of the study results in an
appropriate format.
Results
Quantitative
The MISSION team screened GP records to identify
uncontrolled asthmatics to invite to MISSION clinics. There
were 369 patients identified who had one or more of the criteria
that suggest uncontrolled or potentially severe asthma (high
inhaled corticosteroid dose >500 mcg BDP (Beclomethasone
Diproprionate) , 2 or more exacerbations in the last 12 months
requiring steroids for more than 3 days, any hospital, ED or
OOH contact in the last 12 months, and high SABA usage—>6
inhalers in the last 12 months or reduced lung function FEV1
≤70%). All patients who were identified were approached for
the MISSION project.
Modern Innovative Solutions to Improve Outcomes in
Rapid Access Asthma Clinic Patients and Severe
Asthma Assessment Clinic Patients
The MISSION service: The searches identified 1436 patients
who were manually reviewed by the MISSION team and 460
patients met the criteria. All these patients were invited to the
clinic; 125 were booked in, and 84 attended the RAACs, of
whom 22 were identified for the SAACs.
Primary Care Patients
All patients identified by the GP search but who did not attend
the MISSION clinics will be approached for the study to
maximize the chance of getting the same number of participants
to the number who consents from the MISSION group.
Outpatient Severe Asthma Patients
The severe asthma outpatient clinic at Portsmouth Hospitals
NHS Trust sees 16 new referrals per month. The sample will
be matched to the same as the number of patients attending the
SAACs, that is, 20 patients. All new referrals to the asthma
clinic who meet the inclusion criteria will be included until the
sample size is reached.
Qualitative
All 20 patients from the MISSION SAACs will be approached
for a qualitative interview. Furthermore, all clinical staff who
attended the MISSION RAACs or SAACs will be approached
for an interview with an anticipated number of 10 interviewed
from primary care and 10 from secondary care.
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Discussion
The clinical intervention has been performed and the study has
been ethically approved by the Yorkshire & The Humber-Leeds
East Research Ethics Committee (Reference 15/YH/0136) and
sponsored by Portsmouth Hospitals NHS Trust. The results will
be reported in February 2020.
Conflicts of Interest
None declared.
Multimedia Appendix 1
The study flow chart showing participants’ journey.
[PDF File (Adobe PDF File), 40 KB-Multimedia Appendix 1]
Multimedia Appendix 2
The case record form used for the Modern Innovative Solutions to Improve Outcomes Severe Asthma Assessment Clinics.
[PDF File (Adobe PDF File), 245 KB-Multimedia Appendix 2]
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Abbreviations
ACQ: Asthma Control Questionnaire
ANCOVA:  analysis of covariance
AQLQ: Asthma Quality of Life Questionnaire
CT:  computed tomography
ED:  emergency department
ENT:  ear, nose, and throat
FeNO:  fractional exhaled nitric oxide
FEV1:  forced expiratory volume in 1 second
FVC:  forced vital capacity
GP:  general practitioner
MDT:  multidisciplinary team
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MISSION:  Modern Innovative Solutions to Improve Outcomes
NHS:  National Health Service
OOH:  out-of-hour
PIS:  patient information sheet
RAAC:  Rapid Access Asthma Clinic
RCT:  randomized controlled trial
SAAC:  Severe Asthma Assessment Clinic
SABA:  short-acting beta-agonist
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